Iteos Therapeutics Inc
ITOS10.150USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
388.46MMarket Cap
LossP/E TTM
More Details of Iteos Therapeutics Inc Company
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
Iteos Therapeutics Inc Info
Ticker SymbolITOS
Company nameIteos Therapeutics Inc
IPO dateJul 24, 2020
CEODr. Michel Marcel Detheux, Ph.D.
Number of employees173
Security typeOrdinary Share
Fiscal year-endJul 24
Address321 Arsenal Street
CityWATERTOWN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02472
Phone18572044583
Websitehttps://www.iteostherapeutics.com/
Ticker SymbolITOS
IPO dateJul 24, 2020
CEODr. Michel Marcel Detheux, Ph.D.
Company Executives of Iteos Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Tang
Mr. Kevin Tang
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Thomas Wei
Mr. Thomas Wei
Chief Business Officer
Chief Business Officer
--
--
Mr. Michael Hearne
Mr. Michael Hearne
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Stew Kroll
Mr. Stew Kroll
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Tang
Mr. Kevin Tang
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Thomas Wei
Mr. Thomas Wei
Chief Business Officer
Chief Business Officer
--
--
Mr. Michael Hearne
Mr. Michael Hearne
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Stew Kroll
Mr. Stew Kroll
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
24.18%
Tang Capital Management, LLC
8.66%
BlackRock Institutional Trust Company, N.A.
7.01%
Ridgeback Capital Management, L.P.
4.40%
The Vanguard Group, Inc.
3.76%
Other
51.99%
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
24.18%
Tang Capital Management, LLC
8.66%
BlackRock Institutional Trust Company, N.A.
7.01%
Ridgeback Capital Management, L.P.
4.40%
The Vanguard Group, Inc.
3.76%
Other
51.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
0.21%
Investment Advisor
0.20%
Individual Investor
0.05%
Other
99.54%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
357
46.12M
106.21%
-2.24M
2025Q1
370
38.09M
99.61%
-6.00M
2024Q4
371
35.32M
96.67%
-8.51M
2024Q3
369
38.37M
105.07%
-5.97M
2024Q2
373
37.75M
104.49%
-5.18M
2024Q1
379
35.71M
99.63%
-7.84M
2023Q4
383
36.12M
100.93%
-6.72M
2023Q3
372
36.95M
103.27%
-4.10M
2023Q2
371
36.77M
102.82%
-4.92M
2023Q1
370
37.66M
105.32%
-4.62M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
--
0%
+40.38M
-100.00%
BlackRock Financial Management, Inc.
--
0%
-104.94K
-100.00%
Dimensional Fund Advisors, L.P.
--
0%
-348.49K
-100.00%
Geode Capital Management, L.L.C.
--
0%
+53.41K
-100.00%
OrbiMed Advisors, LLC
--
0%
+700.00K
-100.00%
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.2%
JPMorgan Fundamental Data Science Small Core ETF
0.23%
ALPS Medical Breakthroughs ETF
0.23%
iShares Micro-Cap ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Avantis US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.2%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.23%
ALPS Medical Breakthroughs ETF
Proportion0.23%
iShares Micro-Cap ETF
Proportion0.07%
Fidelity Enhanced Small Cap ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Iteos Therapeutics Inc?
The top five shareholders of Iteos Therapeutics Inc are:
Tang Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
BlackRock Financial Management, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
Dimensional Fund Advisors, L.P. holds 0.00 shares, accounting for 0.00% of the total shares.
Geode Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
OrbiMed Advisors, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Tang Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
BlackRock Financial Management, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
Dimensional Fund Advisors, L.P. holds 0.00 shares, accounting for 0.00% of the total shares.
Geode Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
OrbiMed Advisors, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Iteos Therapeutics Inc?
The top three shareholder types of Iteos Therapeutics Inc are:
EcoR1 Capital, LLC
Tang Capital Management, LLC
BlackRock Institutional Trust Company, N.A.
EcoR1 Capital, LLC
Tang Capital Management, LLC
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Iteos Therapeutics Inc (ITOS)?
As of 2025Q2, 357 institutions hold shares of Iteos Therapeutics Inc, with a combined market value of approximately 46.12M, accounting for 106.21% of the total shares. Compared to 2025Q1, institutional shareholding has increased by 6.60%.
What is the biggest source of revenue for Iteos Therapeutics Inc?
In --, the -- business generated the highest revenue for Iteos Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
